AMIX (Autonomix Medical) Total Assets : $11.95 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Autonomix Medical Total Assets?

Autonomix Medical's Total Assets for the quarter that ended in Dec. 2024 was $11.95 Mil.

During the past 12 months, Autonomix Medical's average Total Assets Growth Rate was -78.20% per year.

Total Assets is connected with ROA %. Autonomix Medical's annualized ROA % for the quarter that ended in Dec. 2024 was -125.24%. Total Assets is also linked to Revenue through Asset Turnover. Autonomix Medical's Asset Turnover for the quarter that ended in Dec. 2024 was 0.00.

Autonomix Medical Total Assets Historical Data

The historical data trend for Autonomix Medical's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Autonomix Medical Total Assets Chart

Autonomix Medical Annual Data

Trend

Mar23

Mar24

Total Assets

0.87

9.41

Autonomix Medical Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Assets	Get a 7-Day Free Trial				1.81	9.41	7.10	5.37	11.95

Autonomix Medical Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Autonomix Medical's Total Assets for the fiscal year that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (A: Mar. 2024 )	+	Total Liabilities (A: Mar. 2024 )
	=	7.628	+	1.779
	=	9.41

Autonomix Medical's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2024 )	+	Total Liabilities (Q: Dec. 2024 )
	=	9.707	+	2.245
	=	11.95

Autonomix Medical (NAS:AMIX) Total Assets Explanation

Total Assets is connected with ROA %.

Autonomix Medical's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %	=	Net Income (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	-10.848	/	( (5.371	+	11.952)	/ 2 )
	=	-10.848	/	8.6615
	=	-125.24 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Autonomix Medical's Asset Turnover for the quarter that ended in Dec. 2024 is

	Asset Turnover
=	Revenue (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
=	0	/	( (5.371	+	11.952)	/ 2 )
=	0	/	8.6615
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Autonomix Medical Total Assets Related Terms

Thank you for viewing the detailed overview of Autonomix Medical's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Autonomix Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Autonomix Medical Inc (NAS:AMIX) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

21 Waterway Avenue, Suite 300, Woodlands, TX, USA, 77380

Website

https://www.autonomix.com

Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.